Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹1,583.00
30.60 (1.90%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹40.16K Cr
MID CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
34.4
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹1,251.6+26.5%
52W High₹1,678.3-5.7%
Current Price
₹1,583.00
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,266.40
Upper Circuit₹1,899.60
Reference Price
₹1,583.00
Investment Checklist
Double Bottom on 1W (BREAKOUT CONFIRMED) — target ₹1773.4
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹1737.5
Volume divergence: Bearish (price up, volume down)
EMA(9) Crossover: Price crossed below EMA(9): Fresh bearish weakness signal.
EMA(20) Crossover: Price crossed below EMA(20): Fresh bearish weakness signal.
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
41%
Trend
NEUTRAL
NEUTRAL
Mixed MA signals — sideways/transition | Bullish MA stack (20>50>200)
EMA20
1589.44
EMA50
1560.74
EMA200
1477.87
Price Action
MIXED
NEUTRAL
Higher Highs5
Higher Lows4
Lower Highs4
Lower Lows5
Support & Resistance Levels
Resistance (Above)
₹1588.80
₹1622.00
₹1678.30
Support (Below)
₹1547.70
₹1530.00
₹1496.98
₹1468.03
₹1412.86
Volume Analysis
TrendDECREASING
Change-23.10%
Unusual VolumeNo
Divergence Detected
Bearish (price up, volume down)
Stop Loss Levels
Fixed Risk
1% Risk₹1567.17
3% Risk₹1535.51
5% Risk₹1503.85
7% Risk (Custom)
₹1472.19Technical Levels
1x ATR (Volatility)₹1528.15
2x ATR (Swing)₹1473.30
3x ATR (Trend)₹1418.45
Immediate Support₹1547.70
Moving Averages
EMA 50 (Trend)₹1560.74
EMA 200 (Long-term)₹1477.87
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹2,161.7 Cr | ₹2,308.9 Cr | ₹2,556.5 Cr | ₹2,392.5 Cr |
| Net Profit | ₹67.8 Cr | ₹233.2 Cr | ₹282.6 Cr | ₹326.3 Cr |
| EPS | — | ₹9.19 | ₹11.14 | ₹12.86 |
| Operating Profit | ₹249 Cr | ₹449.1 Cr | ₹514.5 Cr | ₹571.2 Cr |
ROE
10.62%
ROCE
14.62%
Debt/Equity
0.20
Current Ratio
2.63
OPM
23.87%
NPM
13.64%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 05 Aug 2025 | Dividend - Rs 2 Per Share | DIVIDEND |
| 27 Nov 2024 | Interim Dividend - Rs 2 Per Share | INTERIM_DIVIDEND |
| 06 Aug 2024 | Annual General Meeting/Dividend - Rs 2 Per Share | AGM |
| 22 Nov 2023 | Interim Dividend - Rs 2 Per Share | INTERIM_DIVIDEND |
| 22 Nov 2022 | Interim Dividend - Rs 4 Per Share | INTERIM_DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for IPCALAB
View All
negative
CNBC TV18 - Markets 22h ago
Ipca Labs ties up with biotech firm to develop cancer and autoimmune disease treatments
Ipca Laboratories has signed a global licensing deal with BRL to develop and commercialise biologic therapies for cancer and autoimmune diseases.
GLOBALIPCALABConsumer ServicesHealthcare
neutral
LiveMint - Markets 4d ago
Unichem may finally start paying off for Ipca Laboratories
Ipca stock’s valuation seem reasonable relative to its earnings potential over the next few years. They trade at around 30 times its FY27 estimated earnings
IPCALABUNICHEMLABHealthcare
NEWS
positive
Business Standard - Markets 5d ago
Ipca Laboratories Ltd soars 0.79%, rises for fifth straight session
Ipca Laboratories Ltd is quoting at Rs 1654.8, up 0.79% on the day as on 12:44 IST on the NSE. The stock is up 20.85% in last one year as compared to a 7.43% spurt in NIFTY and a 11.54% spurt in the Nifty Pharma.
AONELIQUIDAONENIFTYAONETMMQ50AONETOTALIPCALABPHARMABEESFinancial ServicesHealthcare